Actively Recruiting
Characterizing Brain Cannabinoid Receptor 1 Using 11COMAR PET Imaging in Opioid Use Disorder
Led by Yale University · Updated on 2026-09-10
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the function of endocannabinoid eCB systems in people diagnosed with opioid use disorder OUD by measuring the availability of cannabinoid receptor 1 CB1R in the brain. This study aims to characterize CB1 receptors using a specialized imaging agent called 11COMAR. The research compares individuals with OUD to healthy volunteers to better understand differences in brain receptor activity. Participants will undergo brain imaging using Positron Emission Tomography PET with the radioligand 11COMAR, which is administered as a drug during the scan. The study involves one-time PET scans performed within four weeks of screening. Both healthy volunteers and individuals with OUD will participate, providing a comparison between these groups. During the study, participants will complete screening, MRI, PET scan, and follow-up visits. Researchers will measure CB1R availability and serum endocannabinoid levels once within four weeks of screening. The study involves no blinding or randomization and is conducted under medical supervision. Participant involvement includes imaging and health assessments to monitor safety and study outcomes over the course of the research.
CONDITIONS
Brief Title
OMAR Opioid Use Disorder
Research Team
A
Anahita Bassir Nia, MD
A
Abby Dewey
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here